Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Dexamethasone+Lenalidomide+Carfilzomib (KRd), Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM)
### Instruction:
Identify the study with the following condition. 
### Input:
Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Dexamethasone+Lenalidomide+Carfilzomib (KRd), Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM) 
### Output:
Popular Name is ASPIRE, Study ID is NCT01080391